Developing safe, effective, and efficient treatments for laryngopharyngeal reflux

LPR reportedly affects approximately 10-30% of the U.S. population. Symptoms include chronic cough, throat clearing, post-nasal drip, hoarseness, globus sensation, and dysphagia.

Revolutionizing the reflux industry™

We aim to create the world's first pepsin inhibitor as a revolutionary form of treatment for reflux.
Accelerated Developent

Repurposing and reformulating a drug with a good safety and tolerability profile allows expeditious assessment in a clinical trial.

Improved Drug Delivery

A new prolonged release oral formulation and dry powder inhaler, allowing local delivery of a low dose, are expected to significantly improve drug delivery and efficacy for reflux.

Corporate Responsibility

N-Zyme is committed to being a leading ethical biopharmaceutical company that works with a network of internationally recognized and world-renowned scientists, physicians, CDMO’s, and regulatory experts.

Our key research

A proteolytic enzyme is the key therapeutic target in biomedical research of LPR

We have shown that fosamprenavir binds to and inhibits pepsin and prevents pepsin-mediated laryngeal inflammation and damage in an in vivo model of LPR.  In support, patients taking HIV inhibitors have a significantly lower incidence of LPR compared to that reported for the general population.
Our Research →

LPR symptoms reduce ones quality of life and contribute to life-threatening illnesses.

LPR affects both children and adults, and the clinical spectrum is extensive.  Patients present with symptoms due to chronic laryngeal irritation, such as chronic cough, throat-clearing, post-nasal drip, dysphonia, globus, dysphagia, and dyspnea. Chronic LPR contributes to serious and life-threatening illness including airway stenosis, reactive airway disease, and laryngeal cancer.  LPR is estimated to affect more than 20% of the United States population and contribute to 10% visits to otolaryngologists.  Despite the high prevalence and disease burden, there’s no effective medical therapy for LPR.
Living with LPR →

Get Informed

Enter your email to get the latest developments on N-Zyme, including our research, clinical trials and corporate reports.

Thank you for joining us.
Something went wrong. Please contact us on
© 2021 N-Zyme Biomedical Inc.
All Rights Reserved